EA201290062A1 - Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений - Google Patents

Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений

Info

Publication number
EA201290062A1
EA201290062A1 EA201290062A EA201290062A EA201290062A1 EA 201290062 A1 EA201290062 A1 EA 201290062A1 EA 201290062 A EA201290062 A EA 201290062A EA 201290062 A EA201290062 A EA 201290062A EA 201290062 A1 EA201290062 A1 EA 201290062A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compound
compounds
heat shock
shock protein
Prior art date
Application number
EA201290062A
Other languages
English (en)
Inventor
Габриэла Чиозис
Тони Тальдоне
Анна Родина
Паллав Патель
Яньлун Кан
Original Assignee
Мемориал Слоун-Кеттеринг Кэнсэ Сентр
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мемориал Слоун-Кеттеринг Кэнсэ Сентр filed Critical Мемориал Слоун-Кеттеринг Кэнсэ Сентр
Publication of EA201290062A1 publication Critical patent/EA201290062A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Настоящее изобретение относится к соединению, представленному общей формулой (I) или (I'), или к фармакологически приемлемым солям указанного соединения; фармацевтическим композициям, содержащим это соединение; способам получения соединения; способам применения указанного соединения для лечения и/или предотвращения различных злокачественных образований или пролиферативных нарушений; способам применения указанного соединения для идентификации биомаркеров для клинической разработки средств для лечения и/или предотвращения злокачественных образований или пролиферативных нарушений и способам применения указанного соединения для идентификации его рационального применения в способах комбинированной терапии, направленной против различных видов рака. В одном варианте реализации настоящее изобретение относится к соединениям, которые с некоторым уровнем специфичности связываются с белком теплового шока 70 (Hsp70). Настоящее изобретение относится к соединениям, которые с некоторым уровнем специфичности связываются с белком теплового шока 70 (Hsp70) и когнатным белком теплового шока 70 (Hsc70).
EA201290062A 2009-08-17 2010-08-17 Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений EA201290062A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27210109P 2009-08-17 2009-08-17
PCT/US2010/045817 WO2011022440A2 (en) 2009-08-17 2010-08-17 Heat shock protein binding compounds, compositions, and methods for making and using same

Publications (1)

Publication Number Publication Date
EA201290062A1 true EA201290062A1 (ru) 2013-09-30

Family

ID=43607564

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290062A EA201290062A1 (ru) 2009-08-17 2010-08-17 Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений

Country Status (13)

Country Link
US (3) US9567318B2 (ru)
EP (2) EP2467142B1 (ru)
JP (3) JP2013502424A (ru)
KR (1) KR101906146B1 (ru)
CN (2) CN108752280A (ru)
AU (1) AU2010284255B2 (ru)
BR (1) BR112012003637A2 (ru)
CA (1) CA2771190C (ru)
EA (1) EA201290062A1 (ru)
ES (2) ES2608670T3 (ru)
MX (1) MX353747B (ru)
NZ (3) NZ598262A (ru)
WO (1) WO2011022440A2 (ru)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
ES2608670T3 (es) 2009-08-17 2017-04-12 Memorial Sloan-Kettering Cancer Center Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
AU2012249322B2 (en) * 2011-04-28 2018-01-04 Sloan-Kettering Institute For Cancer Research HSP90 combination therapy
CA2832504C (en) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
KR102138218B1 (ko) * 2011-07-08 2020-07-28 슬로안-케테링인스티튜트퍼캔서리서치 표지된 ｈｓｐ90 억제제의 용도
WO2013052888A1 (en) * 2011-10-06 2013-04-11 Whitehead Institute For Biomedical Research Hsf 1 as a marker in tumor prognosis and treatment
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2015002994A2 (en) 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
TW201605812A (zh) 2013-09-16 2016-02-16 拜耳製藥股份有限公司 經雙取代之三氟甲基嘧啶酮類及其用途
US9353078B2 (en) 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
MY184202A (en) 2014-01-16 2021-03-25 Fmc Corp Pyrimidinyloxy benzene derivatives as herbicides
ES2699351T3 (es) * 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
SG11201609336PA (en) 2014-05-13 2016-12-29 Sloan Kettering Inst Cancer Hsp70 modulators and methods for making and using the same
WO2016004136A1 (en) 2014-07-01 2016-01-07 Duffey Matthew O Heteroaryl compounds useful as inhibitors of sumo activating enzyme
JP6604664B2 (ja) 2014-08-04 2019-11-13 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
JP6835709B2 (ja) 2014-09-17 2021-02-24 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ９０を標的とした炎症及び感染のイメージング及び療法
WO2016113205A1 (de) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituierte pentafluorethylpyrimidinone und ihre verwendung
US11006631B2 (en) 2015-03-18 2021-05-18 Fmc Corporation Substituted pyrimidinyloxy pyridine derivatives as herbicides
US11000536B2 (en) * 2015-04-30 2021-05-11 Nant Holdings Ip, Llc Patient treatment via teratogenic pharmaceutical compounds
TWI713530B (zh) 2015-06-05 2020-12-21 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CN108024537A (zh) 2015-07-13 2018-05-11 纳幕尔杜邦公司 作为除草剂的芳氧基嘧啶基醚
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
US10647675B2 (en) 2015-09-18 2020-05-12 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
JP7132848B2 (ja) 2015-10-05 2022-09-07 メモリアル スローン ケタリング キャンサー センター 癌の治療のための合理的併用療法
CA3228632A1 (en) * 2015-12-24 2017-06-29 Kyowa Kirin Co., Ltd. .alpha.,.beta.-unsaturated amide compound
ES2776658T3 (es) 2016-01-22 2020-07-31 Janssen Pharmaceutica Nv Nuevos derivados de cianoindolina con sustituyente heteroaromático de 6 miembros como inhibidores de NIK
SI3405196T1 (sl) 2016-01-22 2020-03-31 Janssen Pharmaceutica Nv Novi substituirani derivati cianoindolina kot inhibitorji NIK
US10822311B2 (en) * 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
AU2017276457B2 (en) 2016-06-07 2019-10-03 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
AU2017283769B2 (en) 2016-06-14 2019-08-15 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
CN109641882B (zh) 2016-06-30 2022-10-28 杨森制药有限公司 作为nik抑制剂的杂芳族衍生物
KR102587619B1 (ko) 2016-06-30 2023-10-11 잔센파마슈티카엔.브이. Nik 억제제로서의 시아노인돌린 유도체
CA3030167A1 (en) * 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
US10040831B2 (en) 2016-12-19 2018-08-07 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CN110730678B (zh) 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
IL296456A (en) 2017-01-23 2022-11-01 Revolution Medicines Inc Bicyclics as allosteric shp2 inhibitors
EP4230623A3 (en) 2017-01-23 2023-10-11 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
MA47452A (fr) 2017-02-07 2019-12-18 Oblique Therapeutics Ab Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer
BR112019016248A2 (pt) 2017-02-07 2020-04-14 Oblique Therapeutics Ab piridinas substituídas com hidrocarbilssulfonila e uso das mesmas no tratamento de câncer
WO2018146468A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer
WO2018146469A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
NZ748072A (en) 2017-03-20 2020-06-26 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CA3062135A1 (en) 2017-05-02 2018-11-08 Fmc Corporation Pyrimidinyloxy benzo-fused compounds as herbicides
JP7221202B2 (ja) * 2017-06-23 2023-02-13 協和キリン株式会社 α、β不飽和アミド化合物
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
EP3694848A1 (en) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
US11801284B2 (en) 2017-12-13 2023-10-31 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating motor neuron diseases
EP3724189B1 (en) 2017-12-15 2023-10-04 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
KR20190108079A (ko) * 2018-03-13 2019-09-23 보로노이바이오 주식회사 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
EP3768664B1 (en) * 2018-03-21 2024-09-04 Suzhou Puhe Biopharma Co., Ltd. Pyrazinone derivatives as shp2 inhibitors and uses thereof
CA3096535A1 (en) 2018-04-10 2019-10-17 Revolution Medicines, Inc. Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
PE20211382A1 (es) 2018-04-30 2021-07-27 Ribon Therapeutics Inc Piridazinonas como inhibidoras de parp7
CR20200578A (es) 2018-05-01 2021-02-22 Revolution Medicines Inc Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
WO2020076723A1 (en) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer
KR20210146288A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로사이클릴 화합물 및 이의 용도
EP3931195A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
IL299831A (en) 2019-03-19 2023-03-01 Voronoi Inc The heteroaryl derivative, a method for its production and a pharmaceutical preparation containing it as an effective ingredient
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
EP4051384A1 (en) 2019-10-30 2022-09-07 Ribon Therapeutics Inc. Pyridazinones as parp7 inhibitors
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
JP2022553858A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
EP4055028A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
CN110702483B (zh) * 2019-11-07 2022-05-10 上海海洋大学 一种超快速鉴别海鲜或肉类的预处理方法
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN111646956B (zh) * 2019-11-14 2022-06-03 中山万远新药研发有限公司 一种哌嗪基取代的二苯基亚砜类化合物及其组合物和应用
JP2023505100A (ja) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド 共有ｒａｓ阻害剤及びその使用
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
AU2021206217A1 (en) 2020-01-07 2022-09-01 Revolution Medicines, Inc. SHP2 inhibitor dosing and methods of treating cancer
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.
AR122450A1 (es) 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
CN112487680B (zh) * 2020-11-27 2024-05-03 西安空间无线电技术研究所 一种用于评价和调控离子阱非谐性势的方法
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Ｓｏｓ１阻害剤およびその使用
AU2022235471A1 (en) * 2021-03-10 2023-09-21 Sumitomo Pharma Co., Ltd. Method for producing fusion protein

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB951431A (en) * 1959-03-17 1964-03-04 Wellcome Found Pyrimidine derivatives and the manufacture thereof
US3248393A (en) * 1960-06-23 1966-04-26 Burroughs Wellcome Co 1, 3-diazaphenothiazines and method
GB990857A (en) 1961-10-13 1965-05-05 Wellcome Found 1,3-diazaphenothiazines
CH605828A5 (ru) * 1974-12-24 1978-10-13 Hoffmann La Roche
US4039543A (en) 1974-12-24 1977-08-02 Hoffmann-La Roche Inc. Benzylpyrimidines
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
DE3311703A1 (de) * 1983-03-30 1984-10-04 Bayer Ag, 5090 Leverkusen Harnstoffderivate
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP0723533A1 (en) * 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
DE4423098A1 (de) * 1994-07-01 1996-01-04 Hoechst Ag Verwendung von Pyrimidingruppen enthaltenden konjugierten Verbindungen als Elektrolumineszenzmaterialien
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH09236070A (ja) * 1996-02-29 1997-09-09 Denso Corp スタータ
US5707930A (en) * 1996-09-16 1998-01-13 Zeneca Limited 4-cycloalkyl-5-substituted pyrimidine compounds useful as crop protection agents
AU4198400A (en) 1999-04-06 2000-10-23 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
US6710048B2 (en) * 2000-09-20 2004-03-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
ES2260318T3 (es) 2000-12-18 2006-11-01 Actelion Pharmaceuticals Ltd. Nuevas sulfamidas y su utilizacion como antagonistas del receptor de endotelina.
US6423720B1 (en) * 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
WO2003055860A1 (en) 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
ES2337782T3 (es) 2002-07-29 2010-04-29 Rigel Pharmaceuticals, Inc. Metodos para tratar o prevenir enfermedades autoinmunitarias con compuestos de 2,4-pirimidindiamina.
AR045414A1 (es) 2003-02-13 2005-10-26 Banyu Pharma Co Ltd Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
AU2004268820B2 (en) 2003-08-29 2011-07-21 Cancer Research Technology Ltd Pyrimidothiophene compounds
US20050070712A1 (en) 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
KR100822530B1 (ko) 2004-03-05 2008-04-16 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 및 ｐ2ｘ2/3 길항물질로서의 다이아미노피리미딘
EP1745033A4 (en) * 2004-05-08 2009-08-26 Neurogen Corp 2-ARYLPYRIMIDINES DISUBSTITUTED IN 4,5
KR20070113288A (ko) * 2005-03-16 2007-11-28 탈자진 인코포레이티드 피리미딘 화합물 및 사용 방법
CA2620129C (en) 2005-09-01 2014-12-23 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
US20080124407A1 (en) 2006-10-10 2008-05-29 University Of Washington Inhibiting cyp3a4 induction
CA2671744C (en) 2006-12-08 2012-08-28 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2008210266B2 (en) * 2007-01-31 2013-09-05 Ym Biosciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
TW200911240A (en) 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
US8754094B2 (en) * 2007-08-15 2014-06-17 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
CN102573486A (zh) 2009-06-08 2012-07-11 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
ES2608670T3 (es) 2009-08-17 2017-04-12 Memorial Sloan-Kettering Cancer Center Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
CA2890748A1 (en) 2012-11-13 2014-05-22 Memorial Sloan-Kettering Cancer Center Indole compounds and their use as antimicrobials
SG11201609336PA (en) 2014-05-13 2016-12-29 Sloan Kettering Inst Cancer Hsp70 modulators and methods for making and using the same
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
AU2016324483B2 (en) 2015-09-18 2021-07-29 Memorial Sloan Kettering Cancer Center Methods and compositions of inhibiting DCN1-UBC12 interaction

Also Published As

Publication number Publication date
US20190038626A1 (en) 2019-02-07
JP6465774B2 (ja) 2019-02-06
CA2771190A1 (en) 2011-02-24
AU2010284255B2 (en) 2016-11-17
MX353747B (es) 2018-01-26
EP3205647A3 (en) 2017-09-27
WO2011022440A2 (en) 2011-02-24
EP3205647B1 (en) 2020-05-13
EP2467142A2 (en) 2012-06-27
ES2608670T3 (es) 2017-04-12
KR20120117954A (ko) 2012-10-24
BR112012003637A2 (pt) 2017-04-25
US20120252818A1 (en) 2012-10-04
ES2817700T3 (es) 2021-04-07
WO2011022440A3 (en) 2011-08-11
MX2012001993A (es) 2012-02-29
US9567318B2 (en) 2017-02-14
NZ713361A (en) 2017-06-30
NZ623069A (en) 2015-11-27
KR101906146B1 (ko) 2018-10-10
CN102753177A (zh) 2012-10-24
US10758538B2 (en) 2020-09-01
JP2013502424A (ja) 2013-01-24
EP2467142A4 (en) 2013-03-06
JP2015212306A (ja) 2015-11-26
EP2467142B1 (en) 2016-09-21
CN108752280A (zh) 2018-11-06
US10052325B2 (en) 2018-08-21
CA2771190C (en) 2020-01-21
WO2011022440A9 (en) 2016-11-10
AU2010284255A1 (en) 2012-03-08
EP3205647A2 (en) 2017-08-16
JP2018188476A (ja) 2018-11-29
NZ598262A (en) 2014-05-30
US20170165265A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
EA201290062A1 (ru) Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
CY1119956T1 (el) Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου
EA200801037A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
JP2009527464A5 (ru)
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
BRPI0511350A (pt) composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
TR201807411T4 (tr) DNA-PK inhibitörleri.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
EA201270730A1 (ru) ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201300411A1 (ru) Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
DE602006005084D1 (de) Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
EA200970551A1 (ru) Производные ацетилена и их применение для связывания и визуализации бляшек амилоида